Sign in or create an account to add this stock to your watchlist.
About Aralez Pharmaceuticals (TSE:ARZ)
Aralez Pharmaceuticals Inc. operates as a specialty pharmaceutical company in the United States and Canada. It engages in acquiring, developing, and commercializing products in the areas of cardiovascular, pain management, dermatological allergy, and other indications. It offers Zontivity for the reduction of thrombotic cardiovascular events in patients with heart attack or peripheral arterial disease; Toprol-XL, a cardioselective beta-blocker that is indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia and patients with primary hypercholesterolemia or mixed dyslipidemia; and Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticarial. The company also markets Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Soriatane for the treatment of severe psoriasis and other disorders of keratinization; Proferrin, an iron supplement; Fiorinal and Fiorinal C for the relief of tension type headaches; and Bezalip SR, a pan-peroxisome proliferator-activated receptor activator to treat hyperlipidemia, as well as to increase insulin sensitivity and decrease blood glucose levels for the patients with metabolic syndrome. In addition, it provides out-licensed products, which include VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and Treximet, a migraine medicine. The company was incorporated in 2015 and is headquartered in Mississauga, Canada.
Industry, Sector and Symbol
Industry Gold
Sub-IndustryN/A
SectorBasic Materials
SymbolTSE:ARZ
CUSIPN/A
Phone+1-905-8761118
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-100.42%
Return on Equity-146.16%
Return on Assets-20.43%
Miscellaneous
EmployeesN/A
Outstanding Shares67,011,000
Aralez Pharmaceuticals (TSE:ARZ) Frequently Asked Questions
What is Aralez Pharmaceuticals' stock symbol?
Aralez Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ARZ."
How were Aralez Pharmaceuticals' earnings last quarter?
Aralez Pharmaceuticals (TSE:ARZ) announced its quarterly earnings data on Tuesday, March, 13th. The company reported ($0.48) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.43) by $0.05. The firm earned $35.59 million during the quarter, compared to analyst estimates of $32.38 million. Aralez Pharmaceuticals had a negative net margin of 100.42% and a negative return on equity of 146.16%. View Aralez Pharmaceuticals' Earnings History.
When is Aralez Pharmaceuticals' next earnings date?
Who are some of Aralez Pharmaceuticals' key competitors?
Some companies that are related to Aralez Pharmaceuticals include Golden Star Resources (GSC), Teranga Gold (TGZ), Argonaut Gold (AR), Perseus Mining (PRU), Perseus Mining (PRU), Sabina Gold & Silver (SBB), Gold Standard Ventures (GSV), Roxgold (ROXG), Dalradian Resources (DNA), Golden Star Resources (GSS), Atlantic Gold (AGB), Argonaut Gold (ARNGF), Avesoro Resources (ASO), Tribune Resources (TBR) and Brio Gold (BRIO).
Who are Aralez Pharmaceuticals' key executives?
Aralez Pharmaceuticals' management team includes the folowing people:
- Mr. Adrian Adams, CEO & Director (Age 67)
- Mr. Andrew I. Koven, Pres & Chief Bus. Officer (Age 60)
- Dr. James Patrick Tursi, Chief Medical Officer (Age 53)
- Mr. Michael Kaseta, CFO & Corp. Controller
- Mr. John E. Barnhardt CPA, Principal Accounting Officer and VP of Fin. & Admin. (Age 68)
Has Aralez Pharmaceuticals been receiving favorable news coverage?
News stories about ARZ stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aralez Pharmaceuticals earned a daily sentiment score of 0.13 on Accern's scale. They also assigned press coverage about the company an impact score of 46.00 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
How do I buy shares of Aralez Pharmaceuticals?
Shares of ARZ and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Aralez Pharmaceuticals' stock price today?
One share of ARZ stock can currently be purchased for approximately C$0.54.
How big of a company is Aralez Pharmaceuticals?
Aralez Pharmaceuticals has a market capitalization of C$119.34 million.
How can I contact Aralez Pharmaceuticals?
Aralez Pharmaceuticals' mailing address is 7100 West Credit Ave Suite 101, MISSISSAUGA, ON L5N 0E4, Canada. The company can be reached via phone at +1-905-8761118.
MarketBeat Community Rating for Aralez Pharmaceuticals (ARZ)
MarketBeat's community ratings are surveys of what our community members think about Aralez Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARZ will underperform the S&P 500 over the long term. You may vote once every thirty days.
Aralez Pharmaceuticals (TSE:ARZ) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Aralez Pharmaceuticals in the last 12 months. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.50 | 2.67 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | N/A | N/A | N/A | N/A |
| Price Target Upside: | N/A | N/A | N/A | N/A |
Aralez Pharmaceuticals (TSE:ARZ) Consensus Price Target History
Aralez Pharmaceuticals (TSE:ARZ) Analyst Ratings History
Show:
(Data available from 5/20/2016 forward)
Aralez Pharmaceuticals (TSE:ARZ) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Aralez Pharmaceuticals (TSE ARZ) Insider Trading and Institutional Ownership History
Aralez Pharmaceuticals (TSE ARZ) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/14/2018 | James Patrick Tursi | Insider | Sell | 5,948 | C$0.52 | C$3,092.96 | | |
| 3/19/2018 | James Patrick Tursi | Insider | Sell | 5,950 | C$1.70 | C$10,115.00 | | |
| 12/8/2017 | Arthur S Kirsch | Director | Buy | 3,600 | C$1.45 | C$5,220.00 | | |
| 10/2/2017 | James Patrick Tursi | Insider | Sell | 9,960 | C$2.50 | C$24,900.00 | | |
| 7/28/2017 | Scott J Charles | Insider | Sell | 10,804 | C$1.25 | C$13,505.00 | | |
| 6/23/2017 | Eric Trachtenberg | Insider | Sell | 7,720 | C$1.33 | C$10,267.60 | | |
| 6/15/2017 | Arthur S Kirsch | Director | Buy | 15,000 | C$1.15 | C$17,250.00 | | |
| 6/14/2017 | Arthur S Kirsch | Director | Buy | 50,000 | C$1.17 | C$58,500.00 | | |
| 6/5/2017 | Andrew Koven | Insider | Sell | 1,906 | C$1.28 | C$2,439.68 | | |
| 3/20/2017 | Andrew Koven | Insider | Sell | 7,025 | C$2.41 | C$16,930.25 | | |
| 3/15/2017 | James Patrick Tursi | Insider | Buy | 4,750 | C$2.11 | C$10,022.50 | | |
| 3/15/2017 | Seth Rudnick | Director | Buy | 5,000 | C$2.37 | C$11,850.00 | | |
(Data available from 1/1/2013 forward)
Aralez Pharmaceuticals (TSE ARZ) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Zacks Investment Research Weighs in on Aralez Pharmaceuticals' Q2 2018 Earnings (ARZ)
www.americanbankingnews.com - May 14 at 1:38 AM |
| Aralez Pharmaceuticals (ARZ) Releases Quarterly Earnings Results
www.americanbankingnews.com - May 8 at 10:47 AM |
| Aralez Pharmaceuticals (ARZ) to Release Earnings on Tuesday
www.americanbankingnews.com - May 1 at 11:46 AM |
 | Will Aralez Pharmaceuticals Inc’s (TSE:ARZ) Earnings Grow In The Next Couple Of Years?
finance.yahoo.com - March 27 at 4:32 PM |
| Aralez Pharmaceuticals (ARZ) Given Buy Rating at HC Wainwright
www.americanbankingnews.com - March 25 at 8:16 AM |
| Aralez Pharmaceuticals (ARZ) Insider James Patrick Tursi Sells 5,950 Shares
www.americanbankingnews.com - March 21 at 8:16 PM |
| Aralez Pharmaceuticals Forecasted to Post FY2018 Earnings of ($0.91) Per Share (ARZ)
www.americanbankingnews.com - March 21 at 9:24 AM |
| Brokers Offer Predictions for Aralez Pharmaceuticals' Q1 2018 Earnings (ARZ)
www.americanbankingnews.com - March 20 at 7:46 AM |
| ARLZ: Aralez Set for Strong Revenue Growth in 2018
finance.yahoo.com - March 19 at 4:33 PM |
| Aralez Pharmaceuticals (ARZ) Downgraded to "Accumulate" at Bloom Burton
www.americanbankingnews.com - March 16 at 9:54 PM |
| Does Aralez Pharmaceuticals Inc’s (TSE:ARZ) CEO Salary Compared Well With Others?
finance.yahoo.com - December 28 at 1:38 PM |
| Aralez Pharmaceuticals, Inc. :ARZ-CA: Earnings Analysis: Q3, 2017 By the Numbers : November 14, 2017
finance.yahoo.com - November 14 at 4:35 PM |
| ARLZ: Increasing Revenue Projections for 2018
finance.yahoo.com - November 14 at 2:12 AM |
| Aralez Pharmaceuticals, Inc. – Value Analysis (TORONTO:ARZ) : November 6, 2017
finance.yahoo.com - November 6 at 5:06 PM |
| Aralez Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARZ-CA : November 3, 2017
finance.yahoo.com - November 3 at 9:14 AM |
| Aralez Pharmaceuticals Inc (ARZ) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - November 2 at 3:32 AM |
| Today's Research Reports on Crescita Therapeutics, Centric Health Corporation, Cipher Pharmaceuticals and Aralez Pharmaceuticals
finance.yahoo.com - October 16 at 4:52 PM |
| Aralez Pharmaceuticals Inc (ARZ) Insider Sells C$24,900.00 in Stock
www.americanbankingnews.com - October 4 at 10:42 PM |
| Aralez Pharmaceuticals, Inc. :ARZ-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 15, 2017
finance.yahoo.com - August 15 at 5:03 PM |
| Today's Research Reports on CanniMed Therapeutics Inc., Aralez Pharmaceuticals Inc., Fennec Pharmaceuticals Inc. and Immunovaccine Inc.
finance.yahoo.com - August 8 at 3:55 PM |
| Aralez Pharmaceuticals, Inc. :ARZ-CA: Earnings Analysis: Q1, 2017 By the Numbers : August 3, 2017
finance.yahoo.com - August 3 at 10:31 PM |
| Aralez Pharmaceuticals Inc (TSE:ARZ) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - August 2 at 7:36 AM |
| Insider Selling: Aralez Pharmaceuticals Inc (TSE:ARZ) Insider Sells 10,804 Shares of Stock
www.americanbankingnews.com - July 28 at 10:35 PM |
| Aralez To Report Second Quarter 2017 Financial Results On August 9, 2017
finance.yahoo.com - July 24 at 1:01 PM |
 | Aralez Announces District Court Decision to Uphold VIMOVO (Naproxen/Esomeprazole Magnesium) Patents - PR Newswire (press release)
www.prnewswire.com - June 27 at 8:48 PM |
 | Form 8-K Aralez Pharmaceuticals For: Jun 27
www.streetinsider.com - June 27 at 3:47 PM |
| Aralez Announces National US Commercial Launch Of Zontivity - PR Newswire (press release)
www.prnewswire.com - June 7 at 6:36 AM |
 | Aralez Pharmaceuticals Inc. 2017 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 11 at 4:05 PM |
| Aralez Announces Reduction In U.S. Sales Force And Cost Savings Program - PR Newswire (press release)
www.prnewswire.com - April 7 at 8:07 AM |
| Horizon Pharma (HZNP) Granted Additional USPTO Notice of Allowance With Claims Covering VIMOVO Delayed ... - StreetInsider.com
www.streetinsider.com - March 31 at 3:46 PM |
| Aralez Reports Fourth Quarter And Full-Year 2016 Financial Results - PR Newswire (press release)
www.prnewswire.com - March 13 at 3:45 PM |
| Aralez to Present at the RBC Capital Markets Global Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - February 16 at 3:42 PM |
| Aralez Provides Update on PBM Formulary Status for Yosprala - PR Newswire (press release)
www.prnewswire.com - December 15 at 3:16 PM |
| Aralez to Participate at Two Upcoming Healthcare Conferences - PR Newswire (press release)
www.prnewswire.com - November 30 at 9:31 AM |
 | Aralez To Acquire US Rights To AstraZeneca's Beta Blocker Toprol-XL For $175 Mln
www.nasdaq.com - October 4 at 3:33 PM |
 | AZ agreement with Aralez for Toprol-XL in US
globenewswire.com - October 4 at 3:33 PM |
 | Aralez Pharmaceuticals Inc (ARLZ) Soars on AstraZeneca Deal
investorplace.com - October 4 at 11:01 AM |
 | AstraZeneca cuts Brilinta sales hopes on artery disease failure
uk.finance.yahoo.com - October 4 at 8:23 AM |
| Aralez Pharmaceuticals' Lead Drug Yosprala Approved By The FDA
seekingalpha.com - September 16 at 8:39 AM |
 | Why Aralez Pharmaceuticals Inc Jumped Higher Today
www.fool.com - August 1 at 4:36 PM |
Aralez Pharmaceuticals (TSE:ARZ) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Aralez Pharmaceuticals (TSE ARZ) Stock Chart for Sunday, May, 20, 2018
Loading chart…
